SPX4,280.15+72.88 1.73%
DIA337.83+4.12 1.23%
IXIC13,047.19+267.27 2.09%

BRIEF-Gilead Sciences Statement On U.S. FDA Acceptance Of New Drug Application For Investigational Lenacapavir

BRIEF-Gilead Sciences Statement On U.S. FDA Acceptance Of New Drug Application For Investigational Lenacapavir

Reuters · 07/28/2022 00:30
BRIEF-Gilead Sciences Statement On U.S. FDA Acceptance Of New Drug Application For Investigational Lenacapavir

- Gilead Sciences Inc GILD:

  • GILEAD SCIENCES STATEMENT ON FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INVESTIGATIONAL LENACAPAVIR

  • FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF DECEMBER 27, 2022.

Source text for Eikon: [ID:]

Further company coverage: GILD


((Reuters.briefs@thomsonreuters.com;))